TRI Auditorium
17 Oct 2023 12:00pm1:00pm



A Research Translation Committee Seminar

Date: Tuesday 17 October 2023
Time: 12:00pm - 1:00pm (Followed by a networking lunch till 1.30pm)
Location: TRI Auditorium or Zoom 
(Pleae register for Zoom login details)

Learn about the new clinical trial design capability being introduced by The University of Queensland and what it means for TRI researchers. You’ll also hear about the innovative clinical design journey and a vision for success.

In late 2022, UQ launched the Vice-Chancellor’s Health Research Accelerator (HERA) initiative. Through this initiative, UQ is investing in a new health and medical research model and capabilities to address the most pressing health and medical research challenges of our time.  One of the seven new HERA initiatives is the ULTRA The University of Queensland’s cLinical TRials cApability. The ULTRA program has been created by the University to build capability and capacity in innovative trial design, conduct, analysis and translation. Its vision for ULTRA is to create a world leading interdisciplinary team focused on innovation in clinical trials that leads to more rapid results and improved patient outcomes.


Professor Nadine Foster
Director STARS Education and Research Alliance, The University of Queensland and Metro North Health

Professor Foster is an NHMRC Leadership Fellow and an internationally recognised expert in rehabilitation, health services research and clinical trials. In her role with STARS, the Surgical, Treatment and Rehabilitation Service, Professor Foster leads an interdisciplinary team of allied health professionals, nurses, medical doctors and consumer and community involvement staff across the UQ and STARS hospital partnership, embedding education and research in the healthcare setting. Prior to STARS, Professor Foster was the Research Director for the School of Allied Health Professions at Keele University as well as leading a large team developing and testing interventions and models of healthcare. Professor Foster has  produced 285+ publications and has led or collaborated on more than $113.5 million AUD for research. 

Associate Professor Ingrid Hickman
Principal Research Fellow (Implementation Science in Randomised Controlled Trials), ULTRA – The University of Queensland’s Clinical Trials Capability, Health Research Accelerator (HERA), The University of Queensland

A/Prof Ingrid Hickman is an implementation scientist with more than 20 years’ experience in health services clinical research. Her career has focused on research excellence, strategic leadership and translating scientific evidence into improved clinical care for people with complex chronic conditions. From randomised controlled trials and mechanisms of disease progression through to patient centred co-design of health services, her collaborative approach to research aims to find solutions to health care problems.  Prior to taking up the new role with the ULTRA team, A/Prof Hickman led the Metabolic Obesity Research Group and the Nutrition Research Program at the Princess Alexandra Hospital in Brisbane for more than 12 years. Within this role she has been a passionate advocate for embedding implementation science and methodologies into clinical trials and health services research and has been recognised internationally for her investment in implementation science and clinical workforce capacity building in research translation.

Professor Andrew Martin
The University of Queensland
Professor Andrew Martin has more than 20 years’ experience in clinical trials research, gained from senior roles within research-based pharmaceutical organisations and The University of Sydney.  Professor Martin's specific interest is in the application of optimal study designs and analysis methods to the development and evaluation of health interventions across all phases of development. This includes the incorporation of quality of life and economic evaluations within clinical trials, and the use of decision analytic techniques to model longer term benefits and costs of interventions.

Session Chairs

Dr Amila Suraweera, International Lung Cancer Foundation Fellow, CARP – Cancer & Ageing Research Program; Centre for Genomics and Personalised Health, Queensland University of Technology
Dr Amelia Fotheringham, Research Fellow, Mater Research